A comparative study of the developability of full-length antibodies, fragments, and bispecific formats reveals higher stability risks for engineered constructs
Engineered antibody formats, such as antibody fragments and bispecifics, have the potential to offer improved therapeutic efficacy compared to traditional full-length monoclonal antibodies (mAbs). However, the translation of these non-natural molecules into successful therapeutics can be hampered by...
Saved in:
Published in | mAbs Vol. 16; no. 1; p. 2403156 |
---|---|
Main Authors | , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Taylor & Francis
31.12.2024
Taylor & Francis Group |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Be the first to leave a comment!